Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACRL.L Regulatory News (ACRL)

  • There is currently no data for ACRL

Half Year Trading Update

22 Nov 2023 07:00

RNS Number : 2041U
Accrol Group Holdings PLC
22 November 2023
 

 

22 November 2023

Accrol Group Holdings plc

("Accrol, the "Group" or the "Company")

 

HALF YEAR TRADING UPDATE

Strong performance with margins and volume continuing to grow

 

Accrol (AIM: ACRL), the UK's leading independent tissue converter, announces the following trading update ahead of its Half Year Results for the six months ended 31 October 2023 ("H1 FY24" or the "Period"), which are scheduled to be released in late January 2024.

 

The Board is pleased to report that the Group performed strongly in H1 FY24:

 

· Volume growth continued throughout the Period;

 

· Margins returned to pre-pandemic levels, quicker than forecast, with the Board now expecting Adjusted EBITDA1 for FY24 of at least £21m;

 

· Adjusted net debt2 at 31 October 2023 was £25.5m (H1 FY23 £30.5m), as a result of strong cash generation, driven by the operational efficiencies of the business. The Board now anticipates that adjusted net debt will be close to 1x EBITDA by the full year end.

 

The Group continues to demonstrate its strong market position, building on its strong customer base and market-leading products, and is well positioned to deliver further growth.

 

Gareth Jenkins, Chief Executive Officer of Accrol, said:

 

"We are clearly very pleased with this performance. We continue to deliver by having great quality and value products which meet every consumer's budget. Our strong relationship with the retailers and our robust supply model are ensuring we can continue to deliver a strong set of results in a changing market environment."

 

1

Adjusted EBITDA is defined as profit before finance costs, tax, depreciation, amortisation, separately disclosed items and share based payments

2

Adjusted net debt excludes operating type leases recognised on the balance sheet in accordance with IFRS 16

 

Market expectations as at 21 November 2023 for FY24 (Shore Capital & Zeus): revenue of ÂŁ205m, adjusted EBITDA of ÂŁ20.5m, adjusted profit before tax of ÂŁ10.8m and net debt of ÂŁ20.1m.

 

For further information, please contact:

 

 

Accrol Group Holdings plc

Dan Wright, Executive Chairman

Via Belvedere Communications

Gareth Jenkins, Chief Executive Officer

Chris Welsh, Chief Financial Officer

 

Zeus (Nominated Adviser & Broker) 

 

Dan Bate / Jordan Warburton

Tel: +44 (0) 161 831 1512

Dominic King

Tel: +44 (0) 203 829 5000

Shore Capital Stockbrokers (Joint Broker)

Tel: +44 (0) 20 7408 4090

Malachy McEntyre/ Mark Percy / James Thomas / Isobel Jones

 

Belvedere Communications Limited

Cat Valentine

Tel: +44 (0) 7715 769 078

Keeley Clarke

Tel: +44 (0) 7967 816 525

accrolpr@belvederepr.com

 

Overview of Accrol

 

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's leading discounters and grocery retailers across the UK. The Group now operates from five manufacturing sites suppling the UK tissue wet wipes market valued at cÂŁ2.7bn at retail sales value.

 

For more information, please visit www.accrol.co.uk.

 

Link for Accrol Today video: https://www.accrol.co.uk/our-business/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKDBKKBDBADB
Date   Source Headline
27th Mar 20247:26 amGNWForm 8.5 (EPT/RI) - Accrol Group Holdings Plc
26th Mar 20243:33 pmRNSTR-1
26th Mar 20241:57 pmPRNForm 8.3 - Accrol Group Holdings plc
26th Mar 20241:01 pmRNSForm 8.3 - Accrol Group Holdings Plc
26th Mar 202412:57 pmRNSForm 8.3 - Accrol Group Holdings PLC
26th Mar 202412:00 pmRNSForm 8.3 - Accrol Group Holdings plc
26th Mar 202411:51 amPRNForm 8.3 - Accrol Group Holdings PLC
26th Mar 202410:02 amPRNForm 8.3 - Accrol Group Holdings plc
26th Mar 20249:17 amGNWForm 8.5 (EPT/RI) - Accrol Group Holdings Plc
25th Mar 20245:09 pmPRNForm 8.3 - Accrol Group Holdings PLC
25th Mar 20245:03 pmPRNForm 8.3 - Accrol Group Holdings Plc
25th Mar 20243:08 pmRNSForm 8.3 - ACCROL GROUP HOLDINGS PLC
25th Mar 20242:31 pmRNSForm 8.3 - Accrol Group Holdings
25th Mar 20242:19 pmRNSForm 8.3 - Accrol Group Holdings Plc
25th Mar 20241:33 pmPRNForm 8.3 - Accrol Group Holdings plc
25th Mar 202411:52 amRNSForm 8.3 - Accrol Group Holdings PLC
25th Mar 202411:00 amPRNForm 8.3 - Accrol Group Holdings plc
25th Mar 202410:51 amRNSForm 8 (DD) - Accrol Group Holdings PLC
25th Mar 202410:24 amRNSForm 8.3 - Accrol Group Holdings PLC
25th Mar 20247:59 amGNWForm 8.5 (EPT/RI) - Accrol Group Holdings Plc
22nd Mar 20241:24 pmPRNForm 8.3 - Accrol Group Holdings plc
22nd Mar 202412:28 pmRNSForm 8.3 -Accrol Group Holdings PLC
22nd Mar 20248:17 amRNSForm 8.3 - Accrol Group Holdings plc
22nd Mar 20247:00 amRNSRecommended Cash Offer
1st Mar 20243:52 pmRNSTR-1
8th Feb 20247:00 amRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSTR-1
30th Jan 20247:00 amRNSHalf Year Results
26th Jan 20247:00 amRNSNotice of Results and Investor Webinar
19th Jan 20247:00 amRNSTR-1
18th Jan 20247:00 amRNSAcquisition of Severn Delta Limited
22nd Nov 20237:00 amRNSHalf Year Trading Update
24th Oct 20232:37 pmRNSResult of AGM
18th Oct 202311:52 amRNSTR-1
18th Oct 202311:49 amRNSTR-1
17th Oct 20235:40 pmRNSTR-1
28th Sep 20239:47 amRNSNotice of AGM and Posting of Annual Report 2023
26th Sep 20237:00 amRNSFinal Results 2023
22nd Sep 20237:00 amRNSNotice of Results and Online Presentations
30th Aug 20231:20 pmRNSTR-1
22nd Aug 20237:00 amRNSDirector Dealings
18th Jul 20234:02 pmRNSTR-1
9th Jun 202311:43 amRNSTR-1
16th May 20237:00 amRNSTrading Update
2nd May 20237:00 amRNSBoard Changes
18th Apr 20234:40 pmRNSTR-1
27th Mar 20233:22 pmRNSTR-1
24th Mar 20231:38 pmRNSTR-1
7th Mar 20237:00 amRNSAppointment of Joint Broker
1st Mar 20237:00 amRNSLicensing Agreement with Unilever

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.